SOVREMENNAYA PEDIATRIYA.2016.4(76):62-65; doi10.15574/SP.2016.76.62 

Role of phenotypic and genotypic signs of bronchial asthma in children 

Banadyha N. V., Voloshyn S. B.

I. Ya. Horbachevsky Ternopil State Medical University Ministry of Health of Ukraine, Ternopil

Objectives. To track the composition and effectiveness of emergency treatment in children with different phenotypes of bronchial asthma (BA).

Patients and methods. With the help of in-depth clinical and instrumental examination, it was analyzed the prevalence of certain phenotypes and genotype features of 64 children aged 5 to 18 years with BA who were admitted to hospital. The molecular genetic methods of investigation forsaw the detection of polymorphism Arg16Gly ADRβ2-receptors.

Results. It was found that between the examined patients the phenotype of allergen induced BA dominated in 50.00% of people, the virus induced BA dominated in 15.63% of people, BA provoked by exercise — in 4.69%, and in 4.69% of patients — BA is associated with obesity, in every fourth patient (25.00%) a mixed phenotype was determined. The conducted analysis of emergency treatment in children with different phenotypes showed that regardless of the phenotypic characteristics, the chosen medicine was salbutamol. But analyzing the genotype specifics of polymorphism Arg16Gly ADRβ2-receptors, was found out that patients with persistent course, in which attacks were stopped with help of salbutamol, the prevalence of Arg16Gly genotype was found in 60.00% of people, and in case of efficiency of combined medicine ipratropium bromide/fenoterol genotype Gly16Gly was found in 66.67%.

Conclusions. Comparison of treatment composition of BA exacerbation depending on the severity and phenotype, also the features of genotype polymorphism Arg16Gly ADRβ2-receptors, found that in patients with genotype Gly16Gly ADRβ2-receptor starts the rapid depletion of β2-receptors to β2-agonists.

Key words: bronchial asthma, molecular genetic studies, phenotypes, children.

REFERENCES

1. Mironova ZhA, Trofimov VI, Yanchina ED, Dubina MV. 2009. Assotsiatsiya variantov gena beta 2-adrenoretseptora (ADRB2) i bronhialnoy astmyi. Problemyi klinicheskoy meditsinyi. 1(19): 58—61.

2. Ogorodova LM, Fedorova OS, Bragina EYu i dr. 2007. Geneticheskie markeryi bronhialnoy astmyi u detey, bolnyih atopicheskim dermatitom. Pulmonologiya. 4: 37—40.

3. Balabolkin II, Bryantseva ON, Tihomirov EE i dr. 2008. Geneticheskie markeryi effektivnosti bronhospazmoliticheskoy terapii detey, stradayuschih atopicheskoy bronhialnoy astmoy. Immuno-patologiya, allergologiya, infektologiya. 2: 53—58.

4. Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry bronkhialnii astmi. Nakaz MOZ Ukrainy №868 vid 08.10.2013 r. http://www.moz.gov.ua.

5. Puzyireva VP. 2010. Genetika bronholegochnyih zabolevaniy. Monografiya. Pod red VP Puzyireva, LM Ogorodovoy. Gl red serii AG Chuchalin. Moskva, Holding «Atmosfera»: 160.

6. Sarkisyan LK. 2006. Techenie bronhialnoy astmyi v zavisimosti ot polimorfizma gena ADRB2 Arg16Gly. Avtoref dis kand med nauk. 14.00.05./03.00.15. Rossiyskiy Universitet Druzhbyi Narodov. Moskva: 24.

7. Umanets TR, Lapshin VF. 2010. Bronhialnaya astma i fenotipyi svistyaschih hripov u detey. Klinicheskaya immunologiya Allergologiya Infektologiya. 2: 66—69.

8. Umeda N, Yoshikawa T, Kanazawa H et al. 2008. Association of β2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology. 13(3): 346—352. http://dx.doi.org/10.1111/j.1440-1843.2008.01259.x; PMid:18399855

9. Hizawa N, Makita H, Nasuhara Y et al. 2007. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest. 132: 1485—1492.

10. Thomsen M, Nordestgaard BG, Sethi AA et al. 2012. Beta(2)-adrenergic receptor polymorphisms, asthma and COPD: two large population — based studies. Eur Respir J. 39: 558—566.

11. Carroll CL, Stoltz P, Schramm CM et al. 2009. β2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest. 135(5): 1186—1192.

12. Hawkins GA, Weiss ST, Bleecker ER. 2008. Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics. 9(3): 349—358. http://dx.doi.org/10.2217/14622416.9.3.349; PMid:18303970

13. Global Initiative for Asthma (GINA) A pocket guide for asthma management and prevention (for adults and children older than 5 years) 2015. URL: http://www.ginasthma.com.

14. Manoharan A, Anderson WJ, Lipworth BJ et al. 2013. Influence of β (2)-adrenergic receptor polymorphism on methacholine hyperresponsiveness in asthmatic patients. Ann Allergy Asthma Immunol. 110(3): 161—164.

15. Kim WJ, Oh YM, Sung J et al. 2008. Lung function response to 12-week treatment with combined inhalation of long-acting β2-agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung. 186(6): 381—386. http://dx.doi.org/10.1007/s00408-008-9103-9

16. Thakkinstian A, McEvoy M, Minelli C et al. 2006. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 162(3): 201—211.